skip to Main Content
816-753-7600 info@MRIGlobal.org

MRIGLOBAL SUPPORTS BARDA WITH DEVELOPMENT OF MEDICAL COUNTERMEASURES FOR BIOLOGICAL THREATS

Biomedical Advanced Research and Development Authority (BARDA) Continues Relationship with MRIGlobal in Nonclincial Studies Network

Kansas City, Mo. – MRIGlobal will continue its relationship with the Biomedical Advanced Research and Development Authority (BARDA) in its mission to support development and acquisition of medical countermeasures to prevent or treat biological threats, pandemic influenza, and emerging infectious diseases.

BARDA’s Nonclinical Studies Network (NSN) is a key element in the successful development of medical countermeasures for biological threats.

“We are very pleased to mark seven years as a member of BARDA’s Nonclinical Studies Network,” said Thomas M. Sack, Ph.D., President and Chief Executive Officer. “We look forward to our continued collaboration.”

MRIGlobal will support BARDA’s mission by completing studies regulated under the Good Laboratory Practices (GLP) regulations as well as other unregulated studies which will support the advancement of potential life-saving therapeutics and vaccines.

About BARDA

The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, provides an integrated, systematic approach to the development and purchase of necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies.

The mission of BARDA is to develop and procure medical countermeasures that address the public health and medical consequences of chemical, biological, radiological, and nuclear accidents, incidents and attacks, pandemic influenza, and emerging infectious diseases. Specifically, BARDA supports the advanced development and procurement of drugs, vaccines and other products that are considered priorities for national health security through its programmatic initiatives.

Leave a Reply